- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT02883114
An Open-Label, 2 Treatment Period,Study To Study The Drug Interaction Between Repeated Doses Of Itraconazole And Single Dose Pharmacokinetics (PK) Of PF-06648671 In Healthy Adults.
19 de dezembro de 2016 atualizado por: Pfizer
A Phase 1, Open-label, Two-period, Fixed-sequence Study To Estimate The Effects Of Multiple-dose Administration Of Itraconazole On The Single-dose Pharmacokinetics Of Pf-06648671 In Healthy Adults
This study is to evaluate the effect of multiple doses of itraconazole, the potent cytochrome P450 enzymes (CYP3A) inhibitor, on the pharmacokinetics of PF-06648671 following a single dose administration in healthy subject.
Visão geral do estudo
Status
Concluído
Condições
Intervenção / Tratamento
Descrição detalhada
Based on in vitro data, PF-06648671 was predominantly metabolized by CYP3A and therefore there is a potential risk that PF-06648671 PK will be affected by co-administered drugs that can inhibit CYP3A activity.
This is a clinical drug interaction study to evaluate this potential drug interaction in human.
In this study, healthy volunteers will take a single dose of 25 mg PF-06648671 in period 1 followed by at least 7 day washout.
In period 2, same subjects will take 200 mg itraconazole oral solution once a day for 3 days, followed by co-administration of 200 mg oral solution and a single dose of 25 mg PF-06648671 on day 4 which are dosed approximately one hour apart with itraconazole is given first.
The PF-06648671 PK will be collected 0-48 hours after dose in period 1 and 0-240 hrs in period 2. Safety will also be monitored throughout both periods.
Tipo de estudo
Intervencional
Inscrição (Real)
12
Estágio
- Fase 1
Contactos e Locais
Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.
Locais de estudo
-
-
Connecticut
-
New Haven, Connecticut, Estados Unidos, 06511
- Pfizer New Haven Clinical Research Unit
-
-
Critérios de participação
Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.
Critérios de elegibilidade
Idades elegíveis para estudo
18 anos a 55 anos (Adulto)
Aceita Voluntários Saudáveis
Sim
Gêneros Elegíveis para o Estudo
Tudo
Descrição
Inclusion Criteria:
- Healthy male and/or female subjects of non childbearing potential between the ages of 18 and 55 years at the time of screening, inclusive. Healthy is defined as no clinically relevant abnormalities identified by a detailed medical history, full physical examination, including blood pressure and pulse rate measurement, 12 lead ECG or clinical laboratory tests.
- Body Mass Index (BMI) of 17.5 to 30.5 kg/m2; and a total body weight >50 kg (110 lbs).
- Evidence of a personally signed and dated informed consent document indicating that the subject has been informed of all pertinent aspects of the study.
- Subjects who are willing and able to comply with all scheduled visits, treatment plan, laboratory tests, and other study procedures.
Exclusion Criteria:
- Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at time of dosing).
- Hypersensitivity or previous adverse events due to azole antifungals.
- A positive urine drug testing.
- History of regular alcohol consumption exceeding 7 drinks/week for females or 14 drinks/week for males within 6 months of Screening.
- Use of tobacco or nicotine containing products in excess of the equivalent of 5 cigarettes per day.
- Treatment with an investigational drug within 30 days (or as determined by the local requirement) or 5 half lives preceding the first dose of study medication, whichever is longer.
- Screening supine blood pressure >=140 mm Hg (systolic) or 90 mm Hg (diastolic), following at least 5 minutes of supine rest. If blood pressure (BP) is >=140 mm Hg (systolic) or 90 mm Hg (diastolic), the BP should be repeated two more times and the average of the three BP values should be used to determine the subject's eligibility.
- Screening supine 12 lead ECG demonstrating corrected QT (QTc) >450 msec or a QRS interval >120 msec. If QTc exceeds 450 msec, or QRS exceeds 120 msec, the ECG should be repeated two more times and the average of the three QTc or QRS values should be used to determine the subject's eligibility.
Subjects with ANY of the following abnormalities in clinical laboratory tests at Screening AND at Day 0, as assessed by the study specific laboratory and confirmed by a single repeat, if deemed necessary:
- Aspartate aminotransferase (AST)/ serum glutamic oxaloacetic transaminase (SGOT) or alanine aminotransferase (ALT)/serum glutamic pyruvic transaminase (SGPT) >1x upper limit of normal (ULN);
- Total bilirubin>=1.5 x ULN; subjects with a history of Gilbert's syndrome may have a direct bilirubin measured and would be eligible for this study provided the direct bilirubin is ULN.
- Fertile male subjects who are unwilling or unable to use a highly effective method of contraception as outlined in this protocol for the duration of the study and for at least 28 days, or longer based upon the compound's half life characteristics, after the last dose of investigational product.
- Use of prescription or nonprescription drugs and dietary supplements within 7 days or 5 half lives (whichever is longer) prior to the first dose of investigational product. As an exception, acetaminophen/paracetamol may be used at doses of 1 g/day. Limited use of non prescription medications that are not believed to affect subject safety or the overall results of the study may be permitted on a case by case basis following approval by the sponsor.
- History of hepatitis or positive testing for human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg), hepatitis B surface antibody (HBsAb), hepatitis B core antibody (HBcAb) or hepatitis C antibodies (HCV). As an exception, a positive HBsAb finding as a result of subject vaccination is permissible.
- Blood donation (excluding plasma donations) of approximately 1 pint (500 mL) or more within 60 days prior to dosing.
- Unwilling or unable to comply with the Lifestyle Requirements described in this protocol.
- Subjects who are investigator site staff members directly involved in the conduct of the study and their family members, site staff members otherwise supervised by the investigator, or subjects who are Pfizer employees, including their family members, directly involved in the conduct of the study.
- Any condition possibly affecting drug absorption.
- Have any medical conditions, medical history, or are taking any medications that are contraindicated in the itraconazole prescribing information.
- Other acute or chronic medical or psychiatric condition including recent (within the past year) or active suicidal ideation or behavior or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the subject inappropriate for entry into this study.
Plano de estudo
Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Ciência básica
- Alocação: Randomizado
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
---|---|
Experimental: single cohort
single dose of PF-06648671 in period 1 and 14-day dose of itraconazole plus single dose of PF-06648671 in period 2
|
Subjects will receive a single dose of PF-06648671 25 mg oral suspension on day 1 in period 1 and a single dose on Day 4 in period 2.
Subjects will receive itraconazole 200 mg oral solution once a day for 14 days in period 2
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
---|---|---|
Maximum Observed PF-06648671 Plasma Concentration (Cmax)
Prazo: 0-48 hours in period 1 and 0-240 hours in period 2 following single dose PF-06648671
|
Camx after single dose of 25 mg PF-06648671 in period 1 and period 2
|
0-48 hours in period 1 and 0-240 hours in period 2 following single dose PF-06648671
|
Time to Reach Maximum Observed Plasma concentration (Tmax)
Prazo: 0-48 hours in period 1 and 0-240 hours in period 2
|
Tmax following single doses of PF-06648671 in period 1 and period 2
|
0-48 hours in period 1 and 0-240 hours in period 2
|
Area Under the Curve From Time Zero to Extrapolated Infinite Time in Plasma (AUCinf)
Prazo: 0-48 hours in period 1 and 0-240 hours in period 2
|
AUCinf following single doses of PF-06648671 in period 1 and period 2
|
0-48 hours in period 1 and 0-240 hours in period 2
|
Area Under the Curve from Time Zero to Last Quantifiable Plasma Concentration (AUClast)
Prazo: 0-48 hours in period 1 and 0-240 hours in period 2
|
AUClast following single doses of PF-06648671 in period 1 and period 2
|
0-48 hours in period 1 and 0-240 hours in period 2
|
Plasma Decay Half-life (t1/2)
Prazo: 0-48 hours in period 1 and 0-240 hours in period 2
|
t1/2 following single doses of PF-06648671 in period 1 and period 2
|
0-48 hours in period 1 and 0-240 hours in period 2
|
Apparent Oral Clearance (CL/F)
Prazo: 0-48 hours in period 1 and 0-240 hours in period 2
|
CL/F following single doses of PF-06648671 in period 1 and period 2
|
0-48 hours in period 1 and 0-240 hours in period 2
|
Apparent Volume of Distribution (Vz/F)
Prazo: 0-48 hours in period 1 and 0-240 hours in period 2
|
Vz/F following single doses of PF-06648671 in period 1 and period 2
|
0-48 hours in period 1 and 0-240 hours in period 2
|
Colaboradores e Investigadores
É aqui que você encontrará pessoas e organizações envolvidas com este estudo.
Patrocinador
Publicações e links úteis
A pessoa responsável por inserir informações sobre o estudo fornece voluntariamente essas publicações. Estes podem ser sobre qualquer coisa relacionada ao estudo.
Datas de registro do estudo
Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.
Datas Principais do Estudo
Início do estudo
1 de setembro de 2016
Conclusão Primária (Real)
1 de novembro de 2016
Conclusão do estudo (Real)
1 de novembro de 2016
Datas de inscrição no estudo
Enviado pela primeira vez
25 de agosto de 2016
Enviado pela primeira vez que atendeu aos critérios de CQ
25 de agosto de 2016
Primeira postagem (Estimativa)
30 de agosto de 2016
Atualizações de registro de estudo
Última Atualização Postada (Estimativa)
20 de dezembro de 2016
Última atualização enviada que atendeu aos critérios de controle de qualidade
19 de dezembro de 2016
Última verificação
1 de dezembro de 2016
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
- Efeitos Fisiológicos das Drogas
- Mecanismos Moleculares de Ação Farmacológica
- Agentes Anti-Infecciosos
- Inibidores Enzimáticos
- Hormônios, Substitutos Hormonais e Antagonistas Hormonais
- Inibidores do citocromo P-450 CYP3A
- Inibidores da enzima citocromo P-450
- Antagonistas Hormonais
- Antifúngicos
- Inibidores da Síntese de Esteróides
- Inibidores de 14-alfa desmetilase
- Itraconazol
Outros números de identificação do estudo
- B7991006
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .
Ensaios clínicos em PF-06648671
-
PfizerConcluído
-
PfizerConcluído
-
PfizerConcluído
-
PfizerConcluído
-
University of FloridaConcluídoSintomas gastrointestinais | Frequência das fezes | Tempo de Trânsito GastrointestinalEstados Unidos
-
PfizerConcluído
-
PfizerConcluído